Market insights

Home » Market insights

EMA Approval for Trazimera Marks Another Win for the Trastuzumab Biosimilars Market

Pfizer’s breast cancer drug Trazimera has moved a step closer to joining Celltrion’s Herzuma, Amgen’s Kanjinti, and Merck Sharp & Dohme’s Ontruzant in the race to seize EU market share from Roche’s blockbuster Herceptin, says GlobalData, a leading data and analytics company. In May 2018, the European Medicines Agency (EMA) Committee for Medicinal Products for [...]

FDA Approval of Low Dose RA Drug Olumiant, Gives Eli Lilly and Incyte Edge in Immediate Future

The approval of Olumiant (baricitinib) 2 mg tablets as a once-daily oral medication for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) by the FDA, will give global healthcare leader Eli Lilly and Delaware-based biopharma firm Incyte Corp. a head start over competitors in the RA market, says leading data and analytics company [...]

Immune-Based Gene Therapy Candidates Should Prevail in Oncology

Gene therapy combines a reduced treatment duration with a higher chance of cure unlike conventional oncology treatments such as chemotherapy. However, this novel therapeutic approach requires the delivery of genetic material to the patient, an uncharted territory in oncology, which will necessitate the implementation of new regulatory guidelines and the restructuring of existing treatment algorithms [...]

Amgen Will Maintain its Dominance in the Preventive Migraine Space with the Launch of Aimovig

Amgen’s Aimovig (erenumab) is forecast to be the top-selling drug in the migraine market by 2026, generating nearly $1.4 billion in sales in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan), according to GlobalData, a leading data and analytics company. Aimovig was recently approved by the FDA for the prevention of [...]

UCB Has Potential to Compete in the Psoriasis Market with Cimzia FDA Approval

The recent FDA approval for Cimzia marks UCB’s entrance into the immunodermatology market, a competitive field in which Cimzia could find a niche space. However, there are a number of safe and efficacious biologics in the psoriasis market, and Cimzia could struggle if it is not well received by prescribing physicians and dermatologists, says GlobalData, [...]

Worldwide Prescription Drug Sales Accelerate to $1.2 Trillion by 2024: Unmet Need Drives Annual Compound Growth

Orphan drugs are forecast to remain one of the fastest growth areas of the global pharmaceutical market according to Evaluate’s annual industry report, the “EvaluatePharma World Preview 2018, Outlook to 2024.” The rare disease space is predicted to capture 20% of the total $1.2 trillion market in 2024. Supporting this growth are the launches of [...]

Industry Leaders to Showcase UK Strength in Medicines Manufacturing

Pharmaceutical company GlaxoSmithKline will open the doors of its state-of-the-art site in Stevenage to host the Medicines Manufacturing Industry Partnership (MMIP) Annual Conference 2018. The conference will take place on Thursday 7 June 2018. The conference — Propelling Growth: Taking the Next Step in Innovative Medicines Manufacturing — brings together global companies to showcase the successes and [...]

Retrofitting cybersecurity

In 1982, long before a cybersecurity threat to control system networks was widely recognised, a Trojan horse attack on control system software reportedly caused a huge explosion in a Siberian gas pipeline. Even now, many systems that have been retrofitted for compatibility with the Industrial Internet of Things (IIoT) are not well protected. Here, Robin [...]

CPhI Report Predicts New Finished Product Manufacturing Hub in the Middle East

A new report by CPhI forecasts sizable changes ahead for the pharma markets in the Middle East and Africa during the next few years. It highlights recent regulatory changes, coupled with increased geopolitical stability and rising generics consumption as key drivers in transforming the prospects of pharma manufacturers in the region. The CPhI Middle East [...]

Number of Immuno-Oncology (IO) trials in China Surge by More Than 50% in 2016 and 2017

In recent years, China increased its focus on the clinical trial investigation of immuno-oncology (I/O) drug candidates. The number of clinical trials recorded a compound annual growth rate (CAGR) of approx. 34% since 2008, according to leading data and analytics company GlobalData. GlobalData identified 819 clinical trials that have been initiated in the last 10 [...]